Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI.
Helen MannFrank AndersohnCarolyn BodnarTetsuya MitsudomiTony S K MokJames Chih-Hsin YangChristopher HoylePublished in: Clinical drug investigation (2018)
In this indirect comparison, osimertinib showed a statistically significant improvement in efficacy outcomes versus platinum-based doublet chemotherapy in patients with EGFRm T790M NSCLC who had progressed after EGFR-TKI therapy.